Venture Capital Investors

Vafidemstat

Vafidemstat is a VC investing group that backs technology-based companies.

Venture Investor Overview

Contact Information

Background Information

Overview

Vafidemstat (developmental code name ORY-2001) is an orally administered, brain-penetrant small molecule developed by Oryzon Genomics S.A., a clinical-stage biopharmaceutical company based in Spain. It functions as a dual inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A) and monoamine oxidase B (MAO-B), targeting epigenetic mechanisms implicated in various neuropsychiatric and neurodegenerative disorders. Vafidemstat is currently undergoing Phase II clinical trials for multiple indications, including aggression, Alzheimer's disease, borderline personality disorder, multiple sclerosis, COVID-19 acute respiratory disease, and schizophrenia.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

4/25/2025

Transaction History

Our records indicate that Vafidemstat invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Investor Contacts

Title

Name

Email & Social

Founder

Carlos Buesa

        

Funds

No fund closings have been recorded for this company.

Portfolio Companies

Vafidemstat has invested in only one tech company, according to our database records. If we are missing a portfolio company, please let us know.

Browse more venture capital investors:

VAeX Capital Partners | VAHOCA

Share this article

About Our Venture Capital Investor Database

The venture capital investor data above is provided by VentureDeal.com, a leading supplier of venture capital funding data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary